|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Biomarkers for the early diagnosis of hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC) is the fifth most common cancer and the second leading cause of cancer-related deaths worldwide. Although the prognosis of patients with HCC is generally poor, the5-year survival rate is > 70% if patients are diagnosed at an early stage. However, early diagnosis of HCC is complicated by the coexistence of inflammation and cirrhosis. Thus, novel biomarkers for the early diagnosis of HCC are required. Currently, the diagnosis of HCC without pathological correlation is achieved by analyzing serum α.fetoprotein levels combined with imaging techniques. Advances in genomics and proteomics platforms and biomarker assay techniques over the last decade have resulted in the identification of numerous novel biomarkers and have improved the diagnosis of HCC. The most promising biomarkers,such as glypican-3, osteopontin, Golgi protein-73 and nucleic acids including microRNAs, are most likely to become clinically validated in the near future. These biomarkers are not only useful for early diagnosis of HCC, but also provide insight into the mechanisms driving oncogenesis. In addition, such molecular insight creates the basis for the development of potentially more effective treatment strategies. In this article,we provide an overview of the biomarkers that are currently used for the early diagnosis of HCC. | Nobuhiro Tsuchiya Yu Sawada Itaru Endo Keigo Saito Yasushi Uemura Tetsuya Nakatsura | 2015 | World Journal of Gastroenterology2015，21，37： | 72 |
| 2 | Potentiality of immunotherapy against hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC),the predominant form of primary liver cancer,is the fifth most common cancer worldwide and the second leading cause of cancer-related death. Despite the high incidence,treatment options remain limited for advanced HCC,and as a result prognosis continues to be poor. Current therapeutic options,surgery,chemotherapy and radiotherapy,have only modest efficacy. New treatment modalities to prolong survival and to minimize the risk of adverse response are desperately needed for patients with advanced HCC. Tumor immunotherapy is a promising,novel treatment strategy that may lead to improvements in both treatment-associated toxicity and outcome. The strategies have developed in part through genomic studies that have yielded candidate target molecules and in part through basic biology studies that have defined the pathways and cell types regulating immune response. Here,we summarize the various types of HCC immunotherapy and argue that the newfound field of HCC immunotherapy might provide critical advantages in the effort to improve prognosis of patients with advanced HCC. Already several immunotherapies,such as tumor-associated antigen therapy,immune checkpoint inhibitors and cell transfer immunotherapy,have demonstrated safety and feasibility in HCC patients. Unfortunately,immunotherapy currently has low efficacy in advanced stage HCC patients; overcoming this chal lenge will place immunotherapy at the forefront of HCC treatment,possibly in the near future. | Nobuhiro Tsuchiya Yu Sawada Itaru Endo Yasushi Uemura Tetsuya Nakatsura | 2015 | World Journal of Gastroenterology2015，21，36： | 19 |
| 3 | Long-term outcomes and prognostic factors of patients with obstructive colorectal cancer: A multicenter retrospective cohort study显示文摘AIM: To investigate the long-term oncologic outcomes and prognostic factors in patients with obstructive colorectal cancer(CRC) at multiple Japanese institutions.METHODS: We identified 362 patients diagnosed with obstructive colorectal cancer from January 1, 2002 to December 31, 2012 in Yokohama Clinical Oncology Group's department of gastroenterological surgery. Among them, 234 patients with stage Ⅱ/Ⅲ disease who had undergone surgical resection of their primary lesions were analyzed, retrospectively. We report the long-term outcomes, the risk factors for recurrence, and the prognostic factors.RESULTS: The five-year disease free survival and cancer-specific survival were 50.6% and 80.3%, respectively. A multivariate analysis showed the ASAPS(HR = 2.23, P = 0.026), serum Albumin ≤ 4.0 g/d L(HR = 2.96, P = 0.007), T4 tumor(HR = 2.73, P = 0.002) and R1 resection(HR = 6.56, P = 0.02) to be independent risk factors for recurrence. Furthermore, poorly differentiated cancers(HR = 6.28, P = 0.009), a T4 tumor(HR = 3.46, P = 0.011) and R1 resection(HR = 6.16, P = 0.006) were independent prognostic factors in patients with obstructive CRC.CONCLUSION: The outcomes of patients with obstructive CRC was poor. T4 tumor and R1 resection were found to be independent prognostic factors for both recurrence and survival in patients with obstructive CRC. | Ishibe Atsushi Ota Mitsuyoshi Yamaguchi Kazuya Kaida Syuhei Kamiya Noriyuki Momiyama Masashi Watanabe Akira Sekizawa Kentaro Kamimukai Nobuyuki Sugimasa Natsuko Watanabe Jun Ichikawa Yasushi Kunisaki Chikara Endo Itaru | 2016 | World Journal of Gastroenterology2016，22，22： | 9 |
| 4 | 胆道肿瘤临床实践指南(英文第三版)显示文摘日本肝胆胰外科学会(JSHBPS)于2007年出版第一版胆道肿瘤(胆管癌、胆囊癌及壶腹癌)临床实践指南,于2014年更新第二版,2021年英文第三版胆道肿瘤临床实践指南围绕6个主题提出若干临床问题,基于相关循证医学证据并组织专家讨论后,最终确定推荐意见、推荐强度以及推荐说明。根据证据推荐分级的评估、制订与评价(GRADE)系统,推荐强度被分为1级(强)或者2级(弱)。英文第三版胆道肿瘤临床实践指南中提出的31个临床问题涵盖:(1)预防性治疗;(2)诊断;(3)胆道引流;(4)外科治疗;(5)化疗;(6)放疗。31个临床问题中,14个问题给予推荐强度为强的推荐意见,14个问题给予推荐强度为弱的推荐意见,剩余的3个问题未给予推荐意见。每条推荐意见都进行推荐强度说明。最新版指南基于循证医学证据,为临床提供了重要建议。未来与癌症登记数据库协作将是评估指南和建立新证据的关键。 | Masato Nagino Satoshi Hirano Hideyuki Yoshitomi Taku Aoki Katsuhiko Uesaka Michiaki Unno Tomoki Ebata Masaru Konishi Keiji Sano Kazuaki Shimada Hiroaki Shimizu Ryota Higuchi Toshifumi Wakai Hiroyuki Isayama Takuji Okusaka Toshio Tsuyuguchi Yoshiki Hirooka Junji Furuse Hiroyuki Maguchi Kojiro Suzuki Hideya Yamazaki Hiroshi Kijima Akio Yanagisawa Masahiro Yoshida Yukihiro Yokoyama Takashi Mizuno Itaru Endo 杨翼飞(译) 仇毓东(译) 赵梦珂(译) 伏旭(译) 蔡正华(译) 毛凉(审校) | 2021 | 中华消化外科杂志2021，20，4： | 7 |
| 5 | Two-stage treatment of an unusual haemobilia caused by intrahepatic pseudoaneurysm显示文摘A 84-year-old man with a surgical history of subtotal gastrectomy for gastric cancer was transferred to our department because of a disorder of consciousness. Septic shock due to obstructive suppurative cholangitis secondary to choledocholithiasis was diagnosed. Anemia was also present,and upper gastrointestinal tract endoscopy revealed blood emerging from the Papilla of Vater.The cause of the anemia was identified as haemobilia.Angiography showed a small aneurysm over the artery on segment 3(A3) .The cause of the haemobilia was suspected to be the bleeding into the biliary tree from this aneurysm.Because the patient's general condition was poor,minimally invasive therapy was needed.Transcatheter arterial embolization(TAE) was selected initally.Later,lateral sectionectomy was performed in order to remove the aneurysm on A3. No surgical complication occurred and,after surgery,no haemobilia was identified.In conclusion,a twostage treatment,namely,surgery following TAE,is recommended for patients in a physically poor condition who have haemobilia due to intrahepatic aneurysm. | Kazuhisa Takeda Kuniya Tanaka Itaru Endo Shinji Togo Hiroshi Shimada | 2010 | World Journal of Hepatology2010，2，1： | 2 |
| 6 | Risk Factors and Management of Bile Leakage after Hepatic Resection显示文摘 | Yasuhiko Nagano M.D. Ph.D. Shinji Togo M.D. Ph.D. Kuniya Tanaka M.D. Ph.D. Hidenori Masui M.D. Ph.D. Itaru Endo M.D. Ph.D. Hitoshi Sekido M.D. Ph.D. Kaoru Nagahori M.D. Ph.D. Hiroshi Shimada M.D. Ph.D | 2003 | World Journal of Surgery2003，，6： | 2 |
| 7 | Short-term results of a randomized study between laparoscopic and open surgery in elderly colorectal cancer patients显示文摘 | Shoichi Fujii Atsushi Ishibe Mitsuyoshi Ota Shigeru Yamagishi Kazuteru Watanabe Jun Watanabe Amane Kanazawa Yasushi Ichikawa Mari Oba Satoshi Morita Yojiro Hashiguchi Chikara Kunisaki Itaru Endo | 2014 | Surgical Endoscopy2014，，2： | 2 |
| 8 | Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy,and tumor-targeting S.typhimurium A1-R is superior to first-line chemotherapy显示文摘Cancer of unknown primary(CUP)is a recalcitrant disease with poor prognosis because it lacks standard first-line therapy.CUP consists of diverse malignancy groups,making personalized precision therapy essential.The present study aimed to identify an effective therapy for a CUP patient using a patient-derived orthotopic xenograft(PDOX)model.This paper reports the usefulness of the PDOX model to precisely identify effective and ineffective chemotherapy and to compare the efficacy of S.typhimurium A1-R with first-line chemotherapy using the CUP PDOX model.The present study is the first to use a CUP PDOX model,which was able to precisely distinguish the chemotherapeutic course.We found that a carboplatinum(CAR)-based regimen was effective for this CUP patient.We also demonstrated that S.typhimurium A1-R was more effective against the CUP tumor than first-line chemotherapy.Our results indicate that S.typhimurium A1-R has clinical potential for CUP,a resistant disease that requires effective therapy. | Kentaro Miyake Tasuku Kiyuna Masuyo Miyake Kei Kawaguchi Sang Nam Yoon Zhiying Zhang Kentaro Igarashi Sahar Razmjooei Sintawat Wangsiricharoen Takashi Murakami Yunfeng Li Scott D.Nelson Tara A.Russell Arun S.Singh Yukihiko Hiroshima Masashi Momiyama Ryusei Matsuyama Takashi Chishima Shree Ram Singh Itaru Endo Fritz C.Eilber Robert M.Hoffman | 2018 | Signal Transduction and Targeted Therapy2018，3，1： | 2 |
| 9 | Intrahepatic Cholangiocarcinoma: Rising Frequency, Improved Survival, and Determinants of Outcome After Resection显示文摘 | Itaru Endo Mithat Gonen Adam C. Yopp Kimberly M. Dalal Qin Zhou David Klimstra Michael D?Angelica Ronald P. DeMatteo Yuman Fong Lawrence Schwartz Nancy Kemeny Eileen O?Reilly Ghassan K. Abou-Alfa Hiroshi Shimada Leslie H. Blumgart William R. Jarnagin | 2008 | Annals of Surgery2008，，1： | 1 |
| 10 | Retroportal Hepaticojejunostomy for Extended Resection of Hilar Bile Ducts显示文摘 | Itaru Endo Mitsutaka Sugita Hideki Masunari Kenichi Yoshida Kazuhisa Takeda Hitoshi Sekido Shinji Togo Hiroshi Shimada | 2008 | Journal of Gastrointestinal Surgery2008，，5： | 1 |
| 11 | Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases显示文摘 | Kuniya Tanaka Hiroshi Shimada Kenichi Matsuo Yasuhiko Nagano Itaru Endo Hitoshi Sekido Shinji Togo | 2004 | Surgery2004，，3： | 1 |
| 12 | Prognostic Significance of the Number of Positive Lymph Nodes in Gallbladder Cancer显示文摘 | Itaru Endo Hiroshi Shimada Mikiko Tanabe Yoshiro Fujii Kazuhisa Takeda Daisuke Morioka Kuniya Tanaka Hitoshi Sekido Shinji Togo | 2006 | Journal of Gastrointestinal Surgery2006，，7： | 1 |
| 13 | Usefulness of granular BCAA after hepatectomy for liver cancer complicated with liver cirrhosis显示文摘 | Shinji Togo Kuniya Tanaka Daisuke Morioka Mitsutaka Sugita Michio Ueda Yasuhiko Miura Toru Kubota Yasuhiko Nagano Kenichi Matsuo Itaru Endo Hitoshi Sekido Hiroshi Shimada | 2005 | Nutrition2005，，4： | 1 |
| 14 | Comparison of short, long-term surgical outcomes and mid-term health-related quality of life after laparoscopic and open resection for colorectal cancer: a case-matched control study显示文摘 | Shoichi Fujii Mitsuyoshi Ota Yasushi Ichikawa Shigeru Yamagishi Kazuteru Watanabe Kenji Tatsumi Jun Watanabe Hirokazu Suwa Takashi Oshima Chikara Kunisaki Shigeo Ohki Itaru Endo Hiroshi Shimada | 2010 | International Journal of Colorectal Disease2010，，11： | 1 |
| 15 | Risk Factors and Management of Bile Leakage after Hepatic Resection显示文摘 | Yasuhiko Nagano M.D. Ph.D. Shinji Togo M.D. Ph.D. Kuniya Tanaka M.D. Ph.D. Hidenori Masui M.D. Ph.D. Itaru Endo M.D. Ph.D. Hitoshi Sekido M.D. Ph.D. Kaoru Nagahori M.D. Ph.D. Hiroshi Shimada M.D. Ph.D | 2003 | World Journal of Surgery2003，，6： | 1 |
| 16 | Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma显示文摘 | Yuki Homma Koichi Taniguchi Takashi Murakami Kazuya Nakagawa Masatoshi Nakazawa Ryusei Matsuyama Ryutaro Mori Kazuhisa Takeda Michio Ueda Yasushi Ichikawa Kuniya Tanaka Itaru Endo | 2014 | Annals of Surgical Oncology2014，，2： | 1 |
| 17 | Covered self‐expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer显示文摘 | Kensuke Kubota Takamitsu Sato Seitaro Watanabe Kunihiro Hosono Noritoshi Kobayashi Ryutaro Mori Koichi Taniguchi Ryusei Matsuyama Itaru Endo Atsushi Nakajima | 2014 | Digestive Endoscopy2014，，1： | 1 |
| 18 | Is parenchyma-preserving hepatectomy a noble option in the surgical treatment for high-risk patients with hilar bile duct cancer?显示文摘 | Hiroshi Shimada Itaru Endo Mitsutaka Sugita Hideki Masunari Yoshiro Fujii Kuniya Tanaka Hitoshi Sekido Shinji Togo | 2003 | Langenbeck’s Archives of Surgery2003，，1： | 1 |
| 19 | Prognostic Factors After Resection of Pancreatic Cancer显示文摘 | Michio Ueda Itaru Endo Masayuki Nakashima Yuta Minami Kazuhisa Takeda Kenichi Matsuo Yasuhiko Nagano Kuniya Tanaka Yasushi Ichikawa Shinji Togo Chikara Kunisaki Hiroshi Shimada | 2009 | World Journal of Surgery2009，，1： | 1 |
| 20 | Clinical features of pancreaticobiliary maljunction: update analysis of 2nd Japan-nationwide survey显示文摘 | Yuji Morine Mitsuo Shimada Hideo Takamatsu Tatsuo Araida Itaru Endo Masayuki Kubota Akira Toki Takuo Noda Toshinobu Matsumura Shuichi Miyakawa Hiroki Ishibashi Terumi Kamisawa Hiroshi Shimada | 2013 | Journal of Hepato-Biliary-Pancreatic Sciences2013，，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员